Improving The Prevention And Clinical Management Of Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$236,146.00
Summary
Modern methods of analysis employ complex tools that are not always available or easily understood by doctors making decisions. The dosing of antibiotics is usually constant, even though known factors influence its effectiveness. Similarly, how effective vaccines are can be estimated from routinely available data. This project will develop tools and strategies to assist doctors and public health authorities make the best decisions by improving the analysis of existing data.
Assessing Vaccine Effectiveness Of Publicly Funded Vaccination Programs In Queensland
Funder
National Health and Medical Research Council
Funding Amount
$99,883.00
Summary
I will measure how well three vaccines on the national immunisation schedule prevent disease in Queensland. Pertussis (whooping cough), rotavirus, and varicella (chicken-pox) vaccines will be assessed using routinely collected health data, such as disease notifications and hospitalisations, and vaccination data. The findings of this research will contribute to evaluating the effectiveness of these publicly funded vaccination programs and will provide an evidence base for future decision-making.
RV3 Rotavirus Vaccine: Phase I And II Clinical Trials Of A Human Neonatal Rotavirus Vaccine For The Global Community
Funder
National Health and Medical Research Council
Funding Amount
$1,099,123.00
Summary
Rotavirus infection is the leading cause of gastroenteritis responsible for over 600,000 deaths each year in children less than 5 years. Although 2 commercial vaccines are now available in Australia, the high cost and concern about the risk of side effects are barriers to widespread vaccine introduction. The goal of this study is to develop an effective rotavirus vaccine, administered to newborns that is affordable for the global community, able to be introduced cheaply in developing countries w ....Rotavirus infection is the leading cause of gastroenteritis responsible for over 600,000 deaths each year in children less than 5 years. Although 2 commercial vaccines are now available in Australia, the high cost and concern about the risk of side effects are barriers to widespread vaccine introduction. The goal of this study is to develop an effective rotavirus vaccine, administered to newborns that is affordable for the global community, able to be introduced cheaply in developing countries where the burden of morbidity and mortality is greatest.Read moreRead less
A Case-control Study Of Rotavirus Vaccine Effectiveness Against Gastroenteritis Hospitalisation Of Children In The NT
Funder
National Health and Medical Research Council
Funding Amount
$465,859.00
Summary
Almost 1 out of 5 children in remote Aboriginal communities are hospitalised with diarrhoea caused by rotavirus. This study will evaluate the impact of rotavirus vaccination in preventing these hospitalisations. In addition to making sure that vaccination works and that those at highest risk are receiving the benefits, it will assess the indirect impact against other causes of diarrhoea providing, critical information relevant to the vaccine's broader introduction in developing country settings.